Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

Literature DB >> 17990352

Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

J Rodriguez¹, R Zarate, E Bandres, A Viudez, A Chopitea, J García-Foncillas, I Gil-Bazo.

Abstract

Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, erbitux and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17990352 PMCID： PMC4205433 DOI： 10.3748/wjg.v13.i44.5867

Source DB: PubMed Journal: World J Gastroenterol ISSN： 1007-9327 Impact factor: 5.742

37 in total

1. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531

2. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

Authors: Timothy Kuo; Cheryl D Cho; Joanne Halsey; Heather A Wakelee; Ranjana H Advani; James M Ford; George A Fisher; Branimir I Sikic
Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544

3. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.

Authors: Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Matthew H Kulke; Craig C Earle; Michele Vincitore; Ann Michelini; Susan Sheehan; Charles S Fuchs
Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544

4. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531

5. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

Authors: Helen X Chen; Margaret Mooney; Matthew Boron; Don Vena; Kimberly Mosby; Louise Grochow; Carl Jaffe; Lawrence Rubinstein; James Zwiebel; Richard S Kaplan
Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544

6. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

Authors: Jeremy Kortmansky; Manish A Shah; Andreas Kaubisch; Amanda Weyerbacher; Sandy Yi; William Tong; Rebecca Sowers; Mithat Gonen; Eileen O'reilly; Nancy Kemeny; David I Ilson; Leonard B Saltz; Robert G Maki; David P Kelsen; Gary K Schwartz
Journal: J Clin Oncol Date: 2005-02-07 Impact factor: 44.544

Review 7. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

Authors: Giampietro Gasparini; Raffaele Longo; Roberta Sarmiento; Alessandro Morabito
Journal: Lancet Oncol Date: 2003-10 Impact factor: 41.316

8. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

9. HER2 expression as a potential marker for response to therapy targeted to the EGFR.

Authors: D R Emlet; R Schwartz; K A Brown; A A Pollice; C A Smith; S E Shackney
Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640

10. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

Authors: M L Veronese; W Sun; B Giantonio; J Berlin; J Shults; L Davis; D G Haller; P J O'Dwyer
Journal: Br J Cancer Date: 2005-05-23 Impact factor: 7.640

13 in total

Review 1. Advances in radiotherapy and targeted therapies for rectal cancer.

Authors: Alexandra Sermeus; Wim Leonard; Benedikt Engels; Mark De Ridder
Journal: World J Gastroenterol Date: 2014-01-07 Impact factor: 5.742

2. The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480.

Authors: Yan Ding; Xiaobing Huang; Taiping Liu; Yong Fu; Zhangping Tan; Hong Zheng; Taoli Zhou; Jigang Dai; Wenyue Xu
Journal: Pathol Oncol Res Date: 2012-06-08 Impact factor: 3.201

3. Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis.

Authors: Xueying Lu; Haibo Wei; Xiaojin Zhang; Wenxin Zheng; Cheng Chang; Jinyu Gu
Journal: Oncol Lett Date: 2011-05-09 Impact factor: 2.967

Review 4. Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors: Christine L H Snozek; Dennis J O'Kane; Alicia Algeciras-Schimnich
Journal: J Mol Diagn Date: 2009-07-30 Impact factor: 5.568

8. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Authors: John L Marshall
Journal: J Oncol Date: 2009-12-06 Impact factor: 4.375

Review 9. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Authors: Eyal Mishani; Galith Abourbeh; Martin Eiblmaier; Carolyn J Anderson
Journal: Curr Pharm Des Date: 2008 Impact factor: 3.116

10. Colorectal cancer and NF-κB signaling pathway.

Authors: Parichehr Hassanzadeh
Journal: Gastroenterol Hepatol Bed Bench Date: 2011